Outlook Therapeutics, Inc. 8-K — AI Bull & Bear Analysis

The FDA's decision to overturn the December 2025 CRL represents a major catalyst for Outlook Therapeutics, shifting the narrative from regulatory failure to imminent approval. While the agency's admission of efficacy clears the primary hurdle for LYTENAVA, the focus now shifts to the specifics of the final labeling and the timing of the June 2026 resubmission. The overall impact is a significant reduction in binary risk, although the company must still navigate the final stages of the BLA process and secure the necessary funding to support a commercial launch.